Literature DB >> 3135264

Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

H J Zweerink1, M C Gammon, C F Hutchison, J J Jackson, D Lombardo, K M Miner, J M Puckett, T J Sewell, N H Sigal.   

Abstract

Lymphocytes from healthy volunteers and from cystic fibrosis patients were transformed with Epstein-Barr virus and cultured at a limiting dilution to generate lymphoblastoid cell lines that secreted human monoclonal antibodies specific for lipopolysaccharide (LPS) from Pseudomonas aeruginosa. Three cell lines (RM5, FDD7, and 11F9) produced immunoglobulin M (IgM) antibody species that reacted specifically with P. aeruginosa Fisher immunotypes 2, 4, and 5, respectively, and with LPS extracted from these immunotypes. A fourth cell line (9H10) produced a single IgM antibody species that recognized P. aeruginosa immunotypes 3, 6, and 7 and LPS extracted from them. Monoclonal antibodies secreted by cell lines RM5, FDD7, and 11F9 protected neutropenic mice prophylactically against challenge with P. aeruginosa immunotypes 2, 4, and 5, and those secreted by 9H10 protected against P. aeruginosa immunotypes 3 and 6 but did not protect against immunotype 7. In vivo experiments indicated that antibodies protected mice against infection by increasing the rate of bacterial clearance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135264      PMCID: PMC259495          DOI: 10.1128/iai.56.8.1873-1879.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

Review 1.  The CBA/N mouse strain: an experimental model illustrating the influence of the X-chromosome on immunity.

Authors:  I Scher
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

2.  Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production.

Authors:  L D Stein; N H Sigal
Journal:  Cell Immunol       Date:  1983-07-15       Impact factor: 4.868

3.  Hospital outbreaks caused by Pseudomonas aeruginosa: importance of serogroup O11.

Authors:  J J Farmer; R A Weinstein; C H Zierdt; C D Brokopp
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

4.  Somatic antigens of Pseudomonas aeruginosa. The structure of O-specific polysaccharide chains of P. aeruginosa O:3a, b and O:3a, d lipopolysaccharides.

Authors:  Y A Knirel; E V Vinogradov; A S Shashkov; B A Dmitriev; N K Kochetkov; E S Stanislavsky; G M Mashilova
Journal:  Eur J Biochem       Date:  1982-11

5.  Somatic Antigens of Pseudomonas aeruginosa. The structure of the polysaccharide chain of Ps.aeruginosa O:6 (Lanyi) lipopolysaccharide.

Authors:  B A Dmitriev; N A Kocharova; Y A Knirel; A S Shashkov; N K Kochetkov; E S Stanislavsky; G M Mashilova
Journal:  Eur J Biochem       Date:  1982-06-15

6.  Somatic antigens of Pseudomonas aeruginosa. The structure of the O-specific polysaccharide chains of Ps.aeruginosa O:2 (Lanyi) lipopolysaccharides.

Authors:  Y A Knirel; E V Vinogradov; A S Shashkov; B A Dmitriev; N K Kochetkov; E S Stanislavsky; G M Mashilova
Journal:  Eur J Biochem       Date:  1982-06-15

Review 7.  Infections caused by Pseudomonas aeruginosa.

Authors:  G P Bodey; R Bolivar; V Fainstein; L Jadeja
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

8.  Somatic antigens of Pseudomonas aeruginosa. The structure of O-specific polysaccharide chains of P. aeruginosa O:3(a),c and O:3a,d,e lipopolysaccharides.

Authors:  E V Vinogradov; A A Shashkov; B A Dmitriev; N K Kochetkov; E S Stanislavsky; G M Mashilova
Journal:  Eur J Biochem       Date:  1983-08-01

9.  Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.609

10.  Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae.

Authors:  D E Briles; C Forman; S Hudak; J L Claflin
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

View more
  13 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

2.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

Review 3.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

4.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide.

Authors:  N L Tout; J S Lam
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

6.  Cross-protection against four species of chicken coccidia with a single recombinant antigen.

Authors:  M S Crane; B Goggin; R M Pellegrino; O J Ravino; C Lange; Y D Karkhanis; K E Kirk; P R Chakraborty
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

7.  Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides.

Authors:  A B Lang; E Fürer; J W Larrick; S J Cryz
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

8.  Protection of immunosuppressed mice against infection with pseudomonas aeruginosa by monoclonal antibodies to outer membrane protein OprI.

Authors:  R Rahner; A Eckhardt; M Duchêne; H Domdey; B U von Specht
Journal:  Infection       Date:  1990 Jul-Aug       Impact factor: 3.553

9.  A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Terashima; I Uezumi; T Tomio; M Kato; K Irie; T Okuda; S Yokota; H Noguchi
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.

Authors:  G B Pier; D Thomas; G Small; A Siadak; H Zweerink
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.